Periprocedural Bridging Anticoagulation: Measuring the Impact of a Clinical Trial on Care Delivery

Use of bridging anticoagulation has been shown to be harmful and without benefit in warfarin-treated patients with atrial fibrillation. We performed a quasi-experimental interrupted time series analysis between 2010 and 2017 in the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) collaborative before and after the BRIDGE trial publication (July 2015). Predicted use of bridging at the end of the study period was calculated with and without the effect of the BRIDGE trial after adjustment for patient-level clustering.

About admin

Now Dr. Jack Straw is in charge of the website, and organizes it so that medical care is available to everyone. In addition, he is an active member of the medical community, regularly attending international conferences and sharing his experience and knowledge. Dr. Straw is not only a medical professional and website manager, but also a loving husband and father of his beautiful children.
View all posts by admin →

Leave a Reply

Your email address will not be published. Required fields are marked *